Evidence map›Paper›PMID 38037430›Full record

ReviewJournal of molecular cell biology2024

The capsid revolution.

Ian A Taylor, Ariberto Fassati

Abstract readReview
In one paragraph

Review in Journal of molecular cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ian A TaylorM acromolecular Structure Laboratory, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0002-6763-3852
Ariberto FassatiDivision of Infection and Immunity, University College London, London WC1E 6JF, UK.ORCID 0000-0003-1934-5327

Funding

Canadian Institute of Health Research PJT-178127Francis Crick InstituteUK Medical Research Council MR/W001241/1Wellcome Trust CC2029
6 · The paper itself

Abstract

Lenacapavir, targeting the human immunodeficiency virus type-1 (HIV-1) capsid, is the first-in-class antiretroviral drug recently approved for clinical use. The development of Lenacapavir is attributed to the remarkable progress in our understanding of the capsid protein made during the last few years. Considered little more than a component of the virus shell to be shed early during infection, the capsid has been found to be a key player in the HIV-1 life cycle by interacting with multiple host factors, entering the nucleus, and directing integration. Here, we describe the key advances that led to this 'capsid revolution'.

Indexed as

CapsidCapsid ProteinsHIV-1Anti-HIV AgentsHIV InfectionsHumansAnti-HIV AgentsCapsid ProteinsCPSF6HIV-1 capsidintegrationIP6Lenacapavirnucleusreverse transcription

Identifiers

PMID38037430
PMCPMC11193064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.